Selective organ preservation for the treatment of muscle-invasive transitional cell carcinoma of the bladder: a review of current and future perspectives

References

• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61(2):69-90
   PubMed Web of Science ®Google Scholar
• Edge SB, Byrd D, Compton CC, et al. AJCC cancer staging manual (eds 7). Springer; New York: 2010. XV:649
   Google Scholar
• Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19(3):666-75
   PubMed Web of Science ®Google Scholar
• Gray PJ, Fedewa SA, Shipley WU, et al. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol 2013;63(5):823-9
   PubMed Web of Science ®Google Scholar
• Figueroa AJ, Stein JP, Dickinson M, et al. Radical cystectomy for elderly patients with bladder carcinoma: an updated experience with 404 patients. Cancer 1998;83(1):141-7
   PubMedGoogle Scholar
• Efstathiou JA, Spiegel DY, Shipley WU, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 2012;61(4):705-11
   PubMed Web of Science ®Google Scholar
• James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012;366(16):1477-88
   PubMed Web of Science ®Google Scholar
• Gakis G, Efstathiou J, Lerner SP, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2013;63(1):45-57
   PubMed Web of Science ®Google Scholar
• Quek ML, Basrawala Z, McClung C, Flanigan RC. Radical cystectomy with extended lymphadenectomy in the presence of a pelvic kidney. Urology 2006;68(3):672 e21-2
   Google Scholar
• Cookson MS, Chang SS, Wells N, et al. Complications of radical cystectomy for nonmuscle invasive disease: comparison with muscle invasive disease. J Urol 2003;169(1):101-4
   PubMedGoogle Scholar
• Pruthi RS, Nix J, McRackan D, et al. Robotic-assisted laparoscopic intracorporeal urinary diversion. Eur Urol 2010;57(6):1013-21
   PubMed Web of Science ®Google Scholar
• Kessler TM, Burkhard FC, Studer UE. Clinical indications and outcomes with nerve-sparing cystectomy in patients with bladder cancer. Urol Clin North Am 2005;32(2):165-75
   PubMedGoogle Scholar
• Hautmann RE, de Petriconi R, Gottfried HW, et al. The ileal neobladder: complications and functional results in 363 patients after 11 years of follow-up. J Urol 1999;161(2):422-7. discussion 7-8
   PubMedGoogle Scholar
• Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011;378(9804):1707-16
   PubMed Web of Science ®Google Scholar
• Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366(9503):2087-106
   PubMed Web of Science ®Google Scholar
• Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996;348(9034):1049-54
   PubMed Web of Science ®Google Scholar
• Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326(24):1593-8
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349(22):2091-8
   PubMed Web of Science ®Google Scholar
• Bekelman JE, Handorf EA, Guzzo T, et al. Radical cystectomy versus bladder-preserving therapy for muscle-invasive urothelial carcinoma: examining confounding and misclassification bias in cancer observational comparative effectiveness research. Value Health 2013;16(4):610-18
   PubMed Web of Science ®Google Scholar
• Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol 2010;28(33):4912-18
   PubMedGoogle Scholar
• Lalondrelle S, Huddart R, Warren-Oseni K, et al. Adaptive-predictive organ localization using cone-beam computed tomography for improved accuracy in external beam radiotherapy for bladder cancer. Int J Radiat Oncol Biol Phys 2011;79(3):705-12
   PubMedGoogle Scholar
• McDonald F, Lalondrelle S, Taylor H, et al. Clinical implementation of adaptive hypofractionated bladder radiotherapy for improvement in normal tissue irradiation. Clin Oncol (R Coll Radiol) 2013;25(9):549-56
   PubMedGoogle Scholar
• Vestergaard A, Muren LP, Sondergaard J, et al. Adaptive plan selection vs. re-optimisation in radiotherapy for bladder cancer: a dose accumulation comparison. Radiother Oncol 2013;109(3):457-62
   PubMedGoogle Scholar
• Hoskin P, Dubash S. Bladder conservation for muscle-invasive bladder cancer. Expert Rev Anticancer Ther 2012;12(8):1015-20
   PubMed Web of Science ®Google Scholar
• Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349(9):859-66
   PubMed Web of Science ®Google Scholar
• Splinter TA, Scher HI, Denis L, et al. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer – Genitourinary Group. J Urol 1992;147(3):606-8
   PubMedGoogle Scholar
• Sternberg CN, Pansadoro V, Calabro F, et al. Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder. Ann Oncol 1999;10(11):1301-5
   PubMedGoogle Scholar
• Rodel C, Grabenbauer GG, Kuhn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002;20(14):3061-71
   PubMed Web of Science ®Google Scholar
• Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003;361(9373):1927-34
   PubMed Web of Science ®Google Scholar
• Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005;48(2):202-5. discussion 5-6
   PubMed Web of Science ®Google Scholar
• Griffiths G, Hall R, Sylvester R, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011;29(16):2171-7
   PubMed Web of Science ®Google Scholar
• von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18(17):3068-77
   PubMed Web of Science ®Google Scholar
• Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001;19(10):2638-46
   PubMed Web of Science ®Google Scholar
• Stenzl A, Cowan NC, De Santis M, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011;59(6):1009-18
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Pansadoro V, Calabro F, et al. Can patient selection for bladder preservation be based on response to chemotherapy? Cancer 2003;97(7):1644-52
   PubMedGoogle Scholar
• Huddart RA BA. Selective organ preservation in muscle invasive TCC of the bladder: a biological approach. BAUS Annual Meeting 2005; abstract 112
   Google Scholar
• Paramasivan S, Huddart R, Hall E, et al. Key issues in recruitment to randomised controlled trials with very different interventions: a qualitative investigation of recruitment to the SPARE trial (CRUK/07/011). Trials 2011;12:78
   PubMedGoogle Scholar
• Moynihan C, Lewis R, Hall E, et al. The Patient Deficit Model Overturned: a qualitative study of patients’ perceptions of invitation to participate in a randomized controlled trial comparing selective bladder preservation against surgery in muscle invasive bladder cancer (SPARE, CRUK/07/011). Trials 2012;13(1):228
   PubMedGoogle Scholar
• Hafeez S, Huddart R. Selective organ preservation with neoadjuvant chemotherapy in the treatment of muscle invasive transitional cell carcinoma (TCC) of the bladder. J Clin Oncol 2013;31(Suppl 6): abstract 310
   Google Scholar
• deVere White RW, Lara PN Jr, Goldman B, et al. A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). J Urol 2009;181(6):2476-80. discussion 80-1
   PubMed Web of Science ®Google Scholar
• Holmang S, Johansson SL. Stage Ta-T1 bladder cancer: the relationship between findings at first follow-up cystoscopy and subsequent recurrence and progression. J Urol 2002;167(4):1634-7
   PubMedGoogle Scholar
• Housset M, Maulard C, Chretien Y, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 1993;11(11):2150-7
   PubMed Web of Science ®Google Scholar
• Kachnic LA, Kaufman DS, Heney NM, et al. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 1997;15(3):1022-9
   PubMed Web of Science ®Google Scholar
• Coppin CM, Gospodarowicz MK, James K, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996;14(11):2901-7
   PubMed Web of Science ®Google Scholar
• Choudhury A, Swindell R, Logue JP, et al. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. J Clin Oncol 2011;29(6):733-8
   PubMed Web of Science ®Google Scholar
• Caffo O, Fellin G, Graffer U, et al. Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer: long-term cumulative results of 2 prospective single-institution studies. Cancer 2011;117(6):1190-6
   PubMedGoogle Scholar
• Kaufman DS, Winter KA, Shipley WU, et al. Phase I-II RTOG study [99-06] of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology 2009;73(4):833-7
   PubMed Web of Science ®Google Scholar
• Mitin T, Hunt D, Shipley WU, et al. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol 2013;14(9):863-72
   PubMed Web of Science ®Google Scholar
• Steel G. Basic clinical radiobiology. Oxford University Press; UK: 3rd edition 2002
   Google Scholar
• Shipley WU, Winter KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998;16(11):3576-83
   PubMed Web of Science ®Google Scholar
• Hagan MP, Winter KA, Kaufman DS, et al. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 2003;57(3):665-72
   PubMed Web of Science ®Google Scholar
• Shipley WU, Kaufman DS, Zehr E, et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002;60(1):62-7. discussion 7-8
   PubMed Web of Science ®Google Scholar
• Glynne-Jones R, Hoskin P. Neoadjuvant cisplatin chemotherapy before chemoradiation: a flawed paradigm? J Clin Oncol 2007;25(33):5281-6
   PubMedGoogle Scholar
• Advanced Bladder Cancer Meta-analysis C. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 2005;48(2):189-99. discussion 99-201
   PubMedGoogle Scholar
• Leow JJ, Martin-Doyle W, Rajagopal PS, et al. Adjuvant chemotherapy for invasive bladder cancer: A 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol 2014;66(1):42-54
   PubMed Web of Science ®Google Scholar
• Holzbeierlein JM, Lopez-Corona E, Bochner BH, et al. Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection. J Urol 2004;172(3):878-81
   PubMed Web of Science ®Google Scholar
• Zietman AL, Sacco D, Skowronski U, et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol 2003;170(5):1772-6
   PubMed Web of Science ®Google Scholar
• Efstathiou JA, Bae K, Shipley WU, et al. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol 2009;27(25):4055-61
   PubMed Web of Science ®Google Scholar
• Tester W, Porter A, Asbell S, et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 1993;25(5):783-90
   PubMed Web of Science ®Google Scholar
• Tester W, Caplan R, Heaney J, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 1996;14(1):119-26
   PubMedGoogle Scholar
• Zietman AL, Grocela J, Zehr E, et al. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology 2001;58(3):380-5
   PubMed Web of Science ®Google Scholar
• Weiss C, Wittlinger M, Engehausen DG, et al. Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy. Int J Radiat Oncol Biol Phys 2008;70(5):1502-6
   PubMed Web of Science ®Google Scholar
• Ploussard G, Daneshmand S, Efstathiou JA, et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol 2014;66(1):120-37
   PubMed Web of Science ®Google Scholar
• McDonald F HS, Lallondrelle S, Harris V, et al. Dose-escalated bladder radiotherapy: result of first dose cohort. NCRI conference. 2012
   Google Scholar
• Eisenberg MS, Dorin RP, Bartsch G, et al. Early complications of cystectomy after high dose pelvic radiation. J Urol 2010;184(6):2264-9
   PubMedGoogle Scholar
• Ramani VA, Maddineni SB, Grey BR, Clarke NW. Differential complication rates following radical cystectomy in the irradiated and nonirradiated pelvis. Eur Urol 2010;57(6):1058-63
   PubMedGoogle Scholar
• Hautmann RE, de Petriconi R, Volkmer BG. Neobladder formation after pelvic irradiation. World J Urol 2009;27(1):57-62
   PubMedGoogle Scholar
• Eswara JR, Efstathiou JA, Heney NM, et al. Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer. J Urol 2012;187(2):463-8
   PubMedGoogle Scholar
• Excellence NIfCGfHaC. Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat (DG10) 2013. Available from: http://guidanceniceorguk/DG10 [Last accessed April 2014]
   Google Scholar
• Cancer Genome Atlas Research N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507(7492):315-22
   PubMedGoogle Scholar
• Bellmunt J, Pons F, Orsola A. Molecular determinants of response to cisplatin-based neoadjuvant chemotherapy. Curr Opin Urol 2013;23(5):466-71
   PubMedGoogle Scholar
• Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331(19):1259-64
   PubMed Web of Science ®Google Scholar
• Ferreira CG, Tolis C, Giaccone G. p53 and chemosensitivity. Ann Oncol 1999;10(9):1011-21
   PubMedGoogle Scholar
• Stadler WM, Lerner SP, Groshen S, et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol 2011;29(25):3443-9
   PubMed Web of Science ®Google Scholar
• Choudhury A, Nelson LD, Teo MT, et al. MRE11 Expression Is Predictive of Cause-Specific Survival following Radical Radiotherapy for Muscle-Invasive Bladder Cancer. Cancer Res 2010;70(18):7017-26
   PubMed Web of Science ®Google Scholar
• Hoskin PJ, Sibtain A, Daley FM, Wilson GD. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer 2003;89(7):1290-7
   PubMed Web of Science ®Google Scholar
• Hoskin PJ, Carnell DM, Taylor NJ, et al. Hypoxia in prostate cancer: correlation of BOLD-MRI with pimonidazole immunohistochemistry-initial observations. Int J Radiat Oncol Biol Phys 2007;68(4):1065-71
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;53(5):1192-202
   PubMed Web of Science ®Google Scholar
• Vergis R, Corbishley CM, Norman AR, et al. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 2008;9(4):342-51
   PubMed Web of Science ®Google Scholar
• Ord JJ, Agrawal S, Thamboo TP, et al. An investigation into the prognostic significance of necrosis and hypoxia in high grade and invasive bladder cancer. J Urol 2007;178(2):677-82
   PubMed Web of Science ®Google Scholar
• Eustace A, Irlam JJ, Taylor J, et al. Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial. Radiother Oncol 2013;108(1):40-7
   PubMedGoogle Scholar
• Gallagher DJ, Milowsky MI, Ishill N, et al. Detection of circulating tumor cells in patients with urothelial cancer. Ann Oncol 2009;20(2):305-8
   PubMed Web of Science ®Google Scholar
• Karl A, Tritschler S, Hofmann S, et al. Perioperative search for circulating tumor cells in patients undergoing radical cystectomy for bladder cancer. Eur J Med Res 2009;14(11):487-90
   PubMedGoogle Scholar
• Msaouel P, Koutsilieris M. Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and meta-analysis. BMC Cancer 2011;11:336
   Google Scholar
• de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14(19):6302-9
   PubMed Web of Science ®Google Scholar
• Pantel K, Alix-Panabieres C. Real-time liquid biopsy in cancer patients: fact or fiction? Cancer Res 2013;73(21):6384-8
   PubMed Web of Science ®Google Scholar
• Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014;25(2):152-65
   PubMed Web of Science ®Google Scholar
• Chakravarti A, Winter K, Wu CL, et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2005;62(2):309-17
   PubMedGoogle Scholar
• Searle EJ, Illidge TM, Stratford IJ. Emerging opportunities for the combination of molecularly targeted drugs with radiotherapy. Clin Oncol 2014;26(5):266-76
   Web of Science ®Google Scholar
• Safwat A, Bentzen SM, Turesson I, Hendry JH. Deterministic rather than stochastic factors explain most of the variation in the expression of skin telangiectasia after radiotherapy. Int J Radiat Oncol Biol Phys 2002;52(1):198-204
   PubMed Web of Science ®Google Scholar
• Barnett GC, Coles CE, Elliott RM, et al. Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Lancet Oncol 2012;13(1):65-77
   PubMed Web of Science ®Google Scholar
• West C, Rosenstein BS. Establishment of a radiogenomics consortium. Radiother Oncol 2010;94(1):117-18
   PubMed Web of Science ®Google Scholar
• Hafeez S, Huddart R. Advances in bladder cancer imaging. BMC Med 2013;11:104
   PubMedGoogle Scholar
• Kobayashi S, Koga F, Kajino K, et al. Apparent diffusion coefficient value reflects invasive and proliferative potential of bladder cancer. J Magn Reson Imaging 2014;39(1):172-8
   PubMedGoogle Scholar
• Yoshida S, Koga F, Kobayashi S, et al. Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 2012;83(1):e21-7
   Google Scholar
• Donaldson SB, Bonington SC, Kershaw LE, et al. Dynamic contrast-enhanced MRI in patients with muscle-invasive transitional cell carcinoma of the bladder can distinguish between residual tumour and post-chemotherapy effect. Eur J Radiol 2013;82(12):2161-8
   PubMedGoogle Scholar
• O’Connor JP, Naish JH, Parker GJ, et al. Preliminary study of oxygen-enhanced longitudinal relaxation in MRI: a potential novel biomarker of oxygenation changes in solid tumors. Int J Radiat Oncol Biol Phys 2009;75(4):1209-15
   PubMed Web of Science ®Google Scholar
• Huddart R BA, Lewis R, Bahl A, on behalf of the SPARE TMG. Results of the SPARE feasibility study – selective bladder preservation against radical excision in muscle invasive T2/T3 transitional cell carcinoma of the bladder (CRUK/07/011). Int J Radiat Oncol Biol Phys 2012;84(Suppl 3):S119-S20
   PubMedGoogle Scholar
• Kaufman DS, Shipley WU, Griffin PP, et al. Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med 1993;329(19):1377-82
   PubMed Web of Science ®Google Scholar
• Garcia del Muro X, Condom E, Vigues F, et al. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Cancer 2004;100(9):1859-67
   PubMedGoogle Scholar
• Shariat SF, Chade DC, Karakiewicz PI, et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol 2010;183(1):68-75
   PubMed Web of Science ®Google Scholar
• Font A, Taron M, Gago JL, et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Oncol 2011;22(1):139-44
   PubMed Web of Science ®Google Scholar
• Kawashima A, Nakayama M, Kakuta Y, et al. Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer. Clin Cancer Res 2011;17(8):2561-9
   PubMed Web of Science ®Google Scholar
• Cooke PW, James ND, Ganesan R, et al. Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy. BJU Int 2000;85(7):829-35
   PubMed Web of Science ®Google Scholar
• Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 1994;69(6):1120-5
   PubMedGoogle Scholar
• Nguyen PL, Swanson PE, Jaszcz W, et al. Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. Am J Clin Pathol 1994;101(2):166-76
   PubMedGoogle Scholar
• Slaton JW, Millikan R, Inoue K, et al. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol 2004;171(2 Pt 1):570-4
   PubMedGoogle Scholar
• Pinho MB, Costas F, Sellos J, et al. XAF1 mRNA expression improves progression-free and overall survival for patients with advanced bladder cancer treated with neoadjuvant chemotherapy. Urol Oncol 2009;27(4):382-90
   PubMedGoogle Scholar
• Maluf FC, Cordon-Cardo C, Verbel DA, et al. Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment. Ann Oncol 2006;17(11):1677-86
   PubMed Web of Science ®Google Scholar
• Grossman HB, Tangen CM, Cordon-Cardo C, et al. Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a Southwest Oncology Group Study. Oncol Rep 2006;16(4):807-10
   PubMedGoogle Scholar
• Takata R, Katagiri T, Kanehira M, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 2005;11(7):2625-36
   PubMedGoogle Scholar
• Smith SC, Baras AS, Dancik G, et al. A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol 2011;12(2):137-43
   PubMedGoogle Scholar